Please assess the completion status of the following clinical trial:

Trial Title: Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 21-75~* Body Mass Index (BMI) \>19 kg/m\^2~* Subjects with biopsy/MRE proven NASH \[MRE liver fat ≥ 5%, with elevated liver enzymes ALT \<5x upper limit normal (ULN)\].~* Subjects with NAFLD and MRE shows F0 or greater fibrosis~* Subjects with history suggestive of NAFLD/NASH~* Total bilirubin must be \< 1.5 x ULN and INR must be \< 1.3 at baseline screening.~* TSH and CPK will be within normal limits (WNL) at screening.~* Subjects with type 2 diabetes who are on stable doses of medications (except pioglitazone) to control hyperglycemia and have baseline HbA1c of 10% or lower.~* Hemoglobin must be greater than or equal to 12.0 in males and 11.0 in females.~Exclusion Criteria:~* Medications that may affect glucose metabolism such as corticosteroids, opiates, barbiturates, and anticoagulants.~* Subjects with anemia, and symptoms suggestive of undiagnosed illness, overt hepatic disease, stroke, Alzheimer's disease, autoimmune hepatitis, alcoholism or increased alcohol consumption over the American Diabetes Association (ADA) guidelines.~* Any disorder that may potentially impact the outcome measures.~* Pregnant women and children.~* Subjects planning weight loss or in any weight loss program.~* Subjects taking TZD's, Atazanavir, Indinavir, Ketoconazole, Valproic acid, Silybum marianum and Valeriana officinalis.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Active drug AZ compound (Type: EXPERIMENTAL): AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).

Based on this trial design, predict the completion outcome and termination type (if applicable).